NEW YORK(GenomeWeb) – Wafergen Biosystems today filed a shelf registration to offer up to $30 million of securities from time to time.
Wafergen President and CEO Ivan Trifunovich told GenomeWeb that there are no imminent financing plans. In August, the firm raised $20 million in gross proceeds through an offering of its common stock and warrants.
In a document filed with the US Securities and Exchange Commission, the company said that as part of its shelf registration it may offer from time to time common stock, preferred stock, debt securities, warrants, and units.
In afternoon trading on the Nasdaq, shares of Wafergen were unchanged at $3.17.